Glucocorticoid regulation of proteoglycan synthesis in mesangial cells  by Kuroda, Mari et al.
Kidney International, Vol. 62 (2002), pp. 780–789
Glucocorticoid regulation of proteoglycan synthesis in
mesangial cells
MARI KURODA, HIROYUKI SASAMURA, RYOKO SHIMIZU-HIROTA, MIZUO MIFUNE,
HIDEAKI NAKAYA, EMI KOBAYASHI, MATSUHIKO HAYASHI, and TAKAO SARUTA
Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan
Glucocorticoid regulation of proteoglycan synthesis in mesan- Glomerular disease is known to be associated with wide-
gial cells. spread changes in the amount and composition of the
Background. Proteoglycans are integral components of the mesangial matrix. The major components of this extra-mesangial matrix and glomerular permeability barrier. Recent
cellular matrix include collagens, proteoglycans, and fi-studies have shown that changes in glomerular proteoglycan
bronectin, which together with numerous less abundantexpression may play a major role in the pathogenesis of renal
disease. Steroid hormones are used as first-choice therapy for proteins and glycoproteins fulfill a variety of physiologi-
the treatment of glomerular diseases, however, the effects of cal functions in the normal glomerulus.
glucocorticoids on expression of glomerular proteoglycans are Proteoglycans are an integral component of this extra-unknown.
cellular matrix. These macromolecules have a commonMethods. This study examined the effects of in vitro and in
structure, consisting of a core protein linked to one orvivo administration of dexamethasone on proteoglycan synthe-
sis and gene expression of proteoglycan core proteins using more glycosaminoglycan (GAG) side chains. Due to
rat (RMC) and human (HMC) mesangial cells. their structural features, in particular the strong negative
Results. Treatment of cultured RMC with dexamethasone charge carried by the GAG moiety, proteoglycans haveresulted in a dose- and time-dependent decrease (P  0.05)
many unique functions. These include the ability to bindin both cell-associated and secreted proteoglycan synthesis to
to an array of other molecules such as growth factors,approximately 50% of control levels. This effect was inhibited
by the glucocorticoid antagonist mifepristone, and mimicked by cytokines, enzymes, enzyme inhibitors, and cellular re-
prednisolone or corticosterone treatment. Separation of pro- ceptors, and to regulate their function [1]. Consequently,
teoglycans by ion-exchange and gel permeation chromatogra- the proteoglycan-rich extracellular matrix serves as bothphy suggested that chondrotin sulfate/dermatan sulfate proteo-
a reservoir and a modulator of the actions of a variety ofglycans were down-regulated after steroid treatment. Northern
blot analysis, RT-PCR, Western blot, and promoter activity as- signaling and differentiation factors. In addition, proteo-
says revealed that dexamethasone caused a significant decrease glycans play a direct role in controlling cell growth and
in decorin mRNA (to 61  8% of controls), whereas biglycan differentiation, in modifying cell adhesion, migration and
expression and promoter activity were increased after steroid
development, and in influencing the deposition of othertreatment. A similar trend was found in glomeruli isolated
extracellular matrix components such as collagen. Of inter-from rats treated in vivo with dexamethasone.
Conclusions. These results demonstrate that treatment of est, the proteoglycans perlecan and agrin also play a major
mesangial cells with steroids results in a decrease in total pro- role in forming the glomerular basement membrane neg-
teoglycan synthesis, as well as subtype-specific changes in pro- ative charge barrier that prevents proteinuria [2].
teoglycan core protein gene expression by transcriptional con-
Based on the composition of the GAG side chains, thetrol, furthering our understanding of the effects of steroid
proteoglycans may be classified biochemically into chon-treatment on the renal glomeruli.
droitin sulfate (CSPG), dermatan sulfate (DSPG), and
heparan sulfate proteoglycans (HSPG). A fourth group of
proteoglycans, the keratan sulfate proteoglycans (KSPG)
are not highly expressed in the kidney. More recently,
the use of molecular cloning techniques has revealed theKey words: decorin, biglycan, mesangial matrix, glomerular permeabil-
structure of the major core proteins, resulting in a paral-ity barrier, steroid hormones, dexamethasone, proteoglycans core pro-
tein gene. lel classification based on the core protein moiety. It is
known that the mesangial cell is a major source of theReceived for publication November 27, 2001
proteoglycans found in the renal glomeruli, and thatand in revised form April 17, 2002
Accepted for publication April 19, 2002 these cells produce the CSPG versican, the CS/DSPGs
biglycan and decorin, as well as the HSPG perlecan [3]. 2002 by the International Society of Nephrology
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Recent reports have shown that changes in proteogly- (CPC) in the presence of 5 g of carrier chondroitin
sulfate for one hour at 37C. Precipitated proteoglycanscan expression may play a crucial role in the pathogenesis
of renal disease. It has been shown that dramatic changes were collected on nitrocellulose filters by vacuum filtra-
tion, washed with 1.0% CPC in 20 mmol/L NaCl andin expression of glomerular proteoglycans are character-
istic of a variety of renal diseases in humans, including radio-counted in a liquid scintillation counter. In some
experiments, samples were treated overnight at 37C withprimary glomerulonephritis, diabetic nephrosclerosis, hy-
pertensive nephrosclerosis, and amyloidosis [4–8]. Hu- chondroitinase ABC (10 mU) in 33 mmol/L Tris-HCl, 33
mmol/L sodium acetate, 80g/mL bovine serum albuminman studies also have shown that expression of proteo-
glycans correlates with loss of renal function, suggesting (BSA; pH 8.0), or chondroitinase AC (10 mU) in 33
mmol/L Tris-HCl, 80 g/mL BSA (pH 6.0), or hepariti-an important pathophysiological role for these glycopro-
teins in the progression of renal failure [9]. These clinical nase III (10 mU) in 100 mmol/L sodium acetate, 10
mmol/L calcium acetate (pH 7.0) prior to CPC precipita-findings provide support for the evidence from labora-
tory studies that proteoglycans are involved in events tion. For determination of cell-associated proteoglycan
synthesis, the cell layers were rinsed with phosphate-that control matrix expansion and cell proliferation,
which are the ultimate features of glomerular sclerosis buffered saline (PBS) and lysed in 1 mol/L NaOH. Three
hundred microliters of each sample were neutralized withand renal failure.
Glucocorticoids are widely prescribed for the therapy 2 N acetic acid, and digested with Pronase E (1 mg/mL)
at 55C for 18 hours. After the addition of chondroitinof glomerulonephritis, and are known to be effective both
for the treatment of proteinuria and for the attenuation sulfate (100 g/mL) as a carrier, cell-associated proteo-
glycans were precipitated for three hours at 37C with 1%of the progression of renal failure [10]. However, they
are not effective for all forms of renal disease, and the CPC in 20 mmol/L NaCl. The precipitate was collected
on nitrocellulose filters and treated as described above.mechanisms of actions of glucocorticoids in ameliorating
glomerular disease are still undefined. Despite the wide-
Ion-exchange and molecular sieve chromatographyspread use of glucocorticoid therapy for the treatment
of renal disease, the effects of glucocorticoids on the ex- To separate proteoglycans in the media on the basis
of differences in charge density, ion-exchange chroma-pression of renal proteoglycans are unknown. Therefore,
the aim of this study was to examine the effects of dexa- tography was performed as described previously using
DEAE-Sephacel (Amersham-Pharmacia, Tokyo, Japan)methasone on proteoglycan production by mesangial
cells, to correlate the changes with the effects of in vivo [12]. After application of media containing 35S-sulfate-
labeled proteoglycans from control and dexamethasone-dexamethasone treatment, and to analyze the molecular
basis of the changes in gene expression. treated cells, unbound radioactivity was removed from the
column by washing with 30 mL of wash buffer [8 mol/L
urea, 50 mmol/L Tris (pH 7.5), 2 mmol/L ethylenedi-
METHODS
aminetetraacetic acid (EDTA), 0.1 mol/L NaCl, 0.5%
Culture of rat and human mesangial cells Triton X-100]. Bound radioactivity was eluted with a
NaCl gradient (0.1 to 0.7 mmol/L in the same buffer)Rat mesangial cells (RMC) from Sprague-Dawley rats
were obtained by enzymatic digestion as described pre- and the radioactivity in the collected fractions was quan-
tified by scintillation counting. To separate proteoglycansviously [11], and cultured in RPMI 1640 supplemented
with 10% fetal calf serum (FCS). Human mesangial cells on the basis of their hydrodynamic size, the concentrated
proteoglycans in peak II were collected and subjected to(HMC) were obtained from Clonetics (San Diego, CA,
USA), and cultured in CCMD 180 medium supple- molecular sieve chromatography using Sepharose CL-2B
(Amersham-Pharmacia) following the method of Leemented with 5% FCS.
et al [13]. Samples were applied to a 10 mm  100 cm
Proteoglycan synthesis assays Sepharose CL-2B column in 4 mol/L guanidine buffer
[4 mol/L guanidine, 10 mmol/L EDTA, 0.5% TritonSynthesis of cell-associated and medium-secreted pro-
teoglycans was determined as described by us previously X-100, 50 mmol/L sodium acetate (pH 7.4)] and collected
in 0.5 mL fractions. Radioactivity in the eluted fractions[12]. In brief, quiescent RMC in 24-well plates were
transferred into serum-free media for 24 hours. Follow- was quantified by scintillation counting. The void volume
and total volume were assessed using dextran blue anding serum deprivation, cultures were incubated in RPMI
containing 3H-glucosamine (2 Ci/mL) or sulfate-free phenol red, respectively [14].
medium containing 35S-sulfate (5 Ci/mL) in the presence
Northern blot analysisof dexamethasone (1 mol/L unless otherwise stated)
for 48 hours. The medium was harvested and 300 L of Total RNA was purified from RMC by the acid guani-
dine-phenol-chloroform method, and quantified by mea-the supernatant was incubated with 25 L of 25 mmol/L
MgSO4, and 120 L of 2.5% cetylpyridinium chloride surement of absorbance of 260 nm in a spectrophotome-
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ter. Twenty micrograms of total RNA were denatured were subcloned into the plasmid pCDNA3.1His/Topo
with formamide and formaldehyde at 65C for 10 minutes (Invitrogen, Groningen, The Netherlands) and sequenced
and fractionated by electrophoresis through a 1.0% form- using an automated sequencer.
aldehyde-agarose gel. RNA was stained with ethidium Reaction products were resolved by electrophoresis
bromide to verify integrity and equal loading, transferred through 8% polyacrylamide gels. Gels were dried using
to a nylon filter (Pall BioSupport, East Hills, NY, USA), a gel dryer prior to imaging using a laser image analyzer
then cross linked using an ultraviolet (UV) irradiator (model BAS 2000; Fuji Film).
(Stratagene, La Jolla, CA, USA). Prehybridization was
conducted at 42C for two hours in a buffer containing Western blot analysis
6  SSC (0.9 mol/L sodium chloride, 0.09 mol/L sodium Western blot analysis of proteoglycan core proteins
citrate, pH 7.0), 5  Denhardt’s solution [0.1% (wt/vol) was performed following the method of Kaji et al [14]
polyvinylpyrrolidone, 0.1% (wt/vol) ficoll type 400, 0.1% using anti-human decorin (LF-136) and anti-human bi-
(wt/vol) bovine serum albumin (BSA)], 50% formamide, glycan (LF-51) antibodies [18, 19], which were generously
0.1% sodium dodecyl sulfate (SDS), and sheared, dena- provided by Dr. Fisher (National Institute of Dental and
tured salmon sperm DNA (100g/mL). The cDNA probes
Craniofacial Research, Bethesda, MD, USA). Proteogly-
for decorin [15] and biglycan [16] were generously pro-
cans in the media of HMC treated with or without dexa-vided by Dr. Woessner (Miami University, Miami, FL,
methasone were concentrated on 0.3 mL DEAE-Sepha-USA) and Dr. Dreher (Weis Center for Research, Dan-
cel columns, and then precipitated with 1.3% potassiumville, PA, USA) through Dr. Takagi (Department of Anat-
acetate in 95% ethanol. After digestion with chondroitin-omy, Nihon University School of Medicine, Tokyo, Japan).
ase ABC, the samples were subjected to SDS-polyacryl-Probes for perlecan and versican were obtained by reverse
amide gel electrophoresis (SDS-PAGE) on acrylamide 4transcription-polymerase chain reaction (RT-PCR) as de-
to 12% gradient gels, transferred to nitrocellulose mem-scribed previously [12]. The 1.1 kb human glyceralde-
branes and detected using the enhanced chemilumines-hyde-3-phosphate dehydrogenase (GAPDH) probe was
cence (ECL) Western blotting system (Amersham).purchased from Clontech Laboratories (Palo Alto, CA,
USA). Probes were radiolabeled with -32P dCTP by
Transient transfection and luciferase assaysthe random primer synthesis method (RadPrime DNA
Plasmids containing various lengths of the 5-flankingLabeling System; Gibco BRL, Grand Island, NY, USA).
region of the human biglycan gene cloned upstream ofAfter hybridization, the filter was washed in 0.2  SSC,
0.1% SDS at 42C. Bands were visualized, and incor- the luciferase gene in vector pGL2-Basic (Promega,
porated radioactivity was quantified by scanning with Madison, WI, USA) [20] were generously provided by
a laser image analyzer (model BAS 2000; Fuji Film, Dr. Ungefroren (University of Hamburg, Hamburg,
Tokyo, Japan). Germany). The constructs used were Bgn (1212,	42),
Bgn (985, 	42), Bgn (686, 	42), Bgn (153, 	42),
RT-PCR Bgn (46, 	42). The numbers in parentheses refer to
Reverse transcription-polymerase chain reaction was the positions of the 5- and 3-nucleotides relative to the
performed as described by us previously [17]. One micro- major transcription start site (5 end of exon 1) of the bi-
gram of total RNA was reverse transcribed in a reaction glycan gene. To assess the promoter activity of luciferase
mixture containing 10 mmol/L Tris-HCl (pH 8.3), 50 constructs with and without dexamethasone treatment,
mmol/L KCl, 5 mmol/L MgCl2, 1 mmol/L dNTP, 1 U RMC in 24-well plates were transfected with various bi-
RNase inhibitor, 2.5mol/L (50 pmol) random hexamers glycan promoter-luciferase plasmids (0.5 g) using lipo-
and 2.5 U Moloney murine leukemia virus (MMLV) fectamine plus (Gibco-BRL) as recommended by the
reverse transcriptase in a volume of 20 L. The reverse
manufacturer. Some of the cells were treated with dexa-
transcribed product was amplified with proteoglycan
methasone (1 mol/L) after completion of the transfec-core protein sense and antisense primers in a reaction
tion procedure. A Renilla luciferase construct (pRL-mixture containing 10 mmol/L Tris-HCl (pH 8.3), 50
TK) was used to normalize for changes in transfectionmmol/L KCl, 2 mmol/L MgCl2, 0.2 mmol/L dNTP, 15
efficiency, and the luciferase activities were assessed 24pmol of each primer, 5 Ci 32P-dCTP, and 2.5 U Taq
hours after transfection by the dual luciferase assay (Pro-polymerase using a Perkin-Elmer-Cetus thermal cycler
mega) exactly as recommended by the manufacturer.for 24 cycles (Perkin-Elmer, Norwalk, CT, USA). The
sequences of the primers for decorin, biglycan, versican,
Protein assaysperlecan, and GAPDH were as reported previously [17].
Protein assays were performed by the Lowry methodPreliminary experiments confirmed that the amplifica-
using a commercially available kit (DC protein assay;tions were performed in the linear phase of the amplifi-
cation cycle. In some experiments, reaction products Bio-Rad, Hercules, CA, USA).
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Fig. 1. Effects of glucocorticoids on proteoglycan synthesis in rat mes-
angial cells (RMC) and human mesangial cells (HMC). (A) Effects of
control (Cont) and dexamethasone (Dex, 1 mol/L) on secreted and
cell-associated proteoglycan synthesis in RMC. (B) Effects of Dex 1
mol/L, prednisolone (PSL, 1 mol/L), or corticosterone (B, 1 mol/L)
on secreted proteoglycan synthesis in RMC. Some cells were pretreated
with mifepristone (Mife, 10mol/L) prior to stimulation with dexameth-
asone. (C ) Effects of Dex 1 mol/L on secreted proteoglycan synthesis
in HMC. Results shown are the mean  SEM (N 
 4 per assay point).
*P  0.05, **P  0.01 vs. control.
In vivo studies associated proteoglycan synthesis. To confirm that this
action was mediated by the glucocorticoid receptor, ex-Ten-week-old male SD rats were treated with or with-
periments were performed with the glucocorticoid an-out daily intraperitoneal injections of dexamethasone
tagonist mifepristone (RU-486), as well as the naturally(5 mg/kg/day) for three days using a previously reported
occurring corticosterone and the therapeutic steroidprotocol [21]. After euthanasia, the kidneys were re-
prednisolone. As shown in Figure 1B, the effects of dexa-moved and glomeruli (90% purity) were isolated by
methasone were attenuated by pre-treatment of cellsdifferential sieving [11]. Total RNA was obtained by the
with mifepristone, and mimicked by treatment with corti-acid guanidine-phenol-chloroform method and subjected
costerone or prednisolone, suggesting that the changesto RT-PCR as described above.
observed were due to stimulation of the glucocorticoid
Statistics receptor. Treatment of HMC with dexamethasone caused
a similar reduction in proteoglycan synthesis (Fig. 1C).Results are expressed as the mean  SEM. Statis-
To assess the dose-dependency and time course oftical comparisons were made by analysis of variance
the dexamethasone-induced effects, RMC were treated(ANOVA) followed by Scheffe’s F-test. P values less
with various doses of dexamethasone for 24 hours, orthan 0.05 were considered statistically significant.
with 1 mol/L dexamethasone for various times. Treat-
Materials ment with dexamethasone caused a dose- and time-
dependent reduction of proteoglycan synthesis to ap-Cell culture materials, radioisotopes, and electropho-
proximately 50% of control values after treatment withresis materials were obtained from Gibco-BRL, Amer-
1 mol/L for 24 hours (Fig. 2). In order to characterizesham International plc, and Bio-Rad, respectively. Other
the subclass of the proteoglycans in control and dexa-reagents were obtained from Sigma Chemical Co. (St.
methasone-treated samples, conditioned media wereLouis, MO, USA), unless otherwise stated.
treated with the enzymes chondroitinase ABC, chon-
droitinase AC, and heparitinase prior to CPC precipita-
RESULTS tion. In the case of 35S-sulfate labeled proteoglycans,
Effects of glucocorticoids on proteoglycan synthesis in treatment with chondrotinase ABC and heparitinase re-
RMC and HMC sulted in95% digestion of the incorporated radioactiv-
ity in both control and dexamethasone-treated cells. InTo examine the effects of glucocorticoids on proteo-
the case of 3H-glucosamine, approximately 30 to 35% ofglycan synthesis, mesangial cells were treated with the
the radioactivity remained undigested after treatmentglucocorticoid dexamethasone. As shown in Figure 1A,
with these enzymes (the percentage of the total radioac-treatment of RMC with dexamethasone resulted in a sig-
nificant (P  0.05) decrease in both secreted and cell- tivity digested by chondroitiniase ABC, AC, hepari-
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Fig. 2. (A) Dose dependency and (B) time course of dexamethasone-induced changes in proteoglycan synthesis in RMC. Quiescent RMC were
treated with (A) various doses of dexamethasone for 48 hours or (B) with 1 mol/L dexamethasone for various times, then proteoglycan synthesis
in the media was assayed as described in the Methods section. In panel B the total labeling time was 48 hours. Dexamethasone was added at the
indicated times before the end of the labeling period. Results shown are the mean  SEM (N 
 4 per assay point). *P  0.05, **P  0.01 vs.
control.
Table 1. Analysis of proteoglycan subtype synthesis in media from rat mesangial cells (RMC) with and without dexamethasone treatment
Incorporation cpm/lg protein
Dex () Dex (	)
3H-glucosamine 35S-sulfate 3H-glucosamine 35S-sulfate
Chondroitinase ABC-sensitive incorporation 12614 32015 1098 25427a
Chondroitinase AC-sensitive incorporation 7810 21812 4711a 17012a
Heparitinase-sensitive incorporation 238 6316 186 5524
Results shown are the mean 	 SEM (N 
 6).
a P  0.05
tinase, or undigested were 58%, 36%, 11%, 31% in the
control cells, and 56%, 24%, 9%, 35% in the dexametha-
sone-treated cells, respectively). The changes in the chon-
droitinase ABC-, AC- and heparitinase-sensitive counts
with and without dexamethasone treatment are shown
in Table 1. Treatment of cells with dexamethasone ap-
peared to cause reductions predominantly in chondroi-
tinase ABC- and AC-sensitive proteoglycans (Table 1).
To confirm and clarify these findings, characterization
of the proteoglycan subclass was also performed by ion-
exchange chromatography using DEAE-Sephacel (Fig. 3).
In the supernatants from both control and dexametha-
sone-treated samples, incorporated 35S-sulfate radioac-
tivity eluted from the ion exchange column predomi-
Fig. 3. Analysis of proteoglycans in media from control () and dexa-
nantly at two peaks. The counts from peak I and II were methasone-treated () RMC by DEAE-Sephacel ion-exchange chro-
matography.attenuated by pretreatment with heparitinase and chon-
droitinase ABC, respectively, as reported previously
[22], suggesting that these peaks contained predomi-
nantly HSPG and CS/DSPG. A clear reduction in peak II control and dexamethasone-treated cells were observed,
was seen in the dexamethasone-treated samples, whereas suggesting that dexamethasone did not cause a major
no major changes in peak I were observed, suggesting change in the length of the proteoglycan molecules.
a reduction in CS/DSPG consistent with the results of the
Effects of dexamethasone on proteoglycan coreenzyme digestion experiments. Next, the DEAE-Sepha-
protein mRNA and proteincel peak II samples were applied to a Sepharose CL-2B
molecular sieve column. As shown in Figure 4, no differ- To examine if the changes in proteoglycan synthesis
mediated by dexamethasone involved changes in proteo-ences in the elution position of proteoglycans from the
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significant increase (2- to 3-fold) in the promoter activity
of the biglycan construct Bgn (1212, 	42), as well as
the shorter constructs Bgn (985, 	42) and Bgn (686,
	42). In contrast, no significant increase in promoter
activity was induced by dexamethasone in the case of
the truncated constructs Bgn (152,	42) and Bgn (46,
	42). Of interest, these last two truncated constructs
lacked the two putative GRE motifs in the biglycan pro-
moter region.
Effects of in vivo dexamethasone treatment on
decorin and biglycan mRNA in isolated glomeruli
To confirm that the dexamethasone-induced changes
in decorin and biglycan mRNA were relevant to the in
vivo situation, SD rats were treated with dexamethasoneFig. 4. Analysis of proteoglycans in media from control () and dexa-
methasone-treated () RMC by Sepharose CL-2B gel permeation chro- in vivo, then expression of decorin and biglycan mRNA
matography. Samples were applied after initial fractionation by ion- was examined by RT-PCR. As shown in Figure 7, treat-exchange chromatography, as described in the Methods section. Abbre-
ment of rats for three days with dexamethasone (5 mg/viations are: Vo, void volume; Vt, total volume.
kg/day) caused a significant increase in biglycan mRNA,
in contrast to decorin, which showed a tendency to de-
crease after steroid treatment, consistent with the in vitro
glycan core protein mRNA, Northern blot analysis was results.
performed to assess changes in the major proteoglycan
core proteins expressed in mesangial cells. Since the sig-
DISCUSSIONnals obtained by Northern blot were low in some cases,
RT-PCR also was performed as described previously The extracellular matrix is known to be a rich source
by our group. Comparison of the data obtained using of growth factors, cytokines, and signaling molecules that
these two assay methods revealed consistent results as interact with each other and together regulate cellular
shown in Figure 5. Treatment of RMC with dexametha- function. A key component of this matrix is the biochem-
sone caused a significant (P  0.05) decrease in decorin ically distinct group of glycoproteins known as proteogly-
mRNA, while a similar but non-significant trend was cans, which consist of a core protein covalently linked
seen for versican. On the other hand, expression of to one or more GAG side chains [1]. These proteoglycans
biglycan mRNA was unexpectedly increased by the dexa- have multiple functions, including the control of extracel-
methasone treatment. To confirm these findings, expres- lular matrix assembly through interactions with collagen
sion of the proteoglycan core proteins decorin and bi- proteins, the activation and inactivation of growth factors
glycan in control and dexamethasone-treated samples that may be directly responsible for the development
were examined by Western blot analysis. These experi- and progression of glomerular disease, as well as direct
ments were performed using HMC, since the antibodies effects on cellular actions by interacting with cell surface
used (LF-136 and LF-51) were raised against the human receptors and adhesion molecules.
core proteins. Bands of the expected size (approximately Recent studies have shown that the expression of pro-
45 kD) were visible after chondroitinase ABC diges- teoglycans changes markedly during the course of renal
tion. Consistent with the results of Northern blot analysis disease, and that these changes may play an important
and RT-PCR, expression of decorin appeared decreased, role in the pathogenesis of various common glomerular
whereas biglycan protein appeared increased in the diseases. In primary glomerulonephritis, up-regulation
dexamethasone-treated samples compared to the con- of the CS/DSPGs biglycan and decorin is seen, and the
trols, suggesting differential regulation of these two pro- temporal and spatial patterns of expression of these pro-
teoglycans (Fig. 5E). teoglycans are consistent with a role for these proteogly-
cans in the pathogenesis of rapidly progressive glomeru-
Effects of dexamethasone on biglycan promoter activity lonephritis [4, 5, 23]. On the other hand, a decrease in
glomerular HSPGs has been linked to the proteinuria seenTo examine the mechanisms of the dexamethasone-
induced increase in biglycan mRNA, RMC were trans- in the nephrotic syndrome. A similar increase in glomeru-
lar biglycan and decorin production together with a de-fected with biglycan promoter constructs using lipofec-
tamine, and promoter activity with or without dexameth- crease in HSPG has been found in diabetic nephropathy
[6–8]. Urinary excretion of decorin has been found to beasone treatment was assessed by the dual luciferase
assay. As shown in Figure 6, dexamethasone caused a increased in both membranous nephropathy and diabetic
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Fig. 5. Effects of dexamethasone on proteoglycan core protein mRNA in RMC. RMC were treated with dexamethasone (1 mol/L) for the
indicated times, and levels of (A) decorin, (B) biglycan, (C ) versican, and (D) perlecan mRNA were assayed by RT-PCR and Northern blot
analysis. Upper panels show representative image of Northern blot assay; middle panels are representative images of RT-PCR; lower panels show
the results of laser densitometric quantitation of results from the RT-PCR assay. Results shown are the mean  SEM (N 
 4 per assay point).
*P 0.05, **P  0.01 vs. control. (E) Effects of dexamethasone on decorin and biglycan core protein expression in HMC. HMC were treated
with or without dexamethasone (Dex, 1 mol/L) for 48 hours, and levels of secreted decorin and biglycan were examined by Western blot analysis
as described in the Methods section.
Fig. 6. Effects of dexamethasone on biglycan promoter activity in RMC. RMC were transfected with the indicated biglycan promoter-luciferase
constructs, then treated with ( ) or without () dexamethasone (1 mol/L) as described in the Methods section. Results shown are the mean 
SEM (N 
 4 per assay point). *P 0.05, **P  0.01 vs. Dex ().
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DSPG decorin, a significant decrease in mRNA levels
was induced by dexamethasone. In contrast, the levels
of biglycan mRNA were unexpectedly increased. To cor-
roborate these findings, Western blot analysis of the bi-
glycan and decorin core proteins was performed, with
consistent results. Moreover, in vivo studies confirmed
that dexamethasone treatment up-regulates glomerular
biglycan gene expression.
What is the significance of the dexamethasone-induced
changes in decorin and biglycan expression? Both de-
Fig. 7. Effects of in vivo dexamethasone treatment on decorin ( ) corin and biglycan are CS/DSPG, which belong to the
and biglycan () mRNA levels in isolated glomeruli. Sprague-Dawley family of proteoglycans of relatively small molecular size
rats were treated with daily intraperitoneal injections of dexamethasone
that contain characteristic leucine-rich repeats and are(5 mg/kg/day) for 3 days, then glomeruli were isolated, and levels of
decorin and biglycan mRNA were assayed by RT-PCR as described in referred to as SLRPs (small leucine-rich proteoglycans)
the Methods section (N 
 6). *P  0.05 vs. control. [28]. These proteoglycans have a variety of important
functions, including the control of collagen deposition
through interactions with multiple collagens including col-
lagen type I, type V, type VI and type XIV [29–31]. Thesenephropathy [6, 24]. Of interest, Vleming et al reported
interactions may be critical in a number of biologicalthat proteoglycan expression in the kidney was a pre-
processes, such as maintenance and assembly of the col-dictor of the severity of renal failure [9]. Taken together,
lagenous scaffold of the extracellular matrix duringthese results suggest that proteoglycans are intimately
growth, development, and wound healing. Indeed, tar-involved in the pathogenesis of glomerular disease.
geted deletion of the decorin and biglycan leads to devel-Since treatment with steroids plays a central role in
opmental abnormalities and weakness in tissues con-
the therapy of glomerulonephritis, we examined the reg-
taining high amounts of collagen, such as skin and bone
ulation of proteoglycans by glucocorticoid hormones.
[32, 33]. In contrast, over-expression of proteoglycans is
We found that dexamethasone reduced total proteogly- found not only in glomerular disease, but also in other
can synthesis in both rat and human cells via a glucocorti- disease states such as atherosclerosis [34]. Thus, the glu-
coid receptor-mediate pathway. These results were not cocorticoid-induced down-regulation of mesangial pro-
specific to dexamethasone and were seen also with corti- teoglycans could serve to attenuate pathological accu-
costerone, which is the major natural glucocorticoid in mulation of extracellular matrix components during
the rat, as well as the therapeutic steroid hormone pred- glomerular disease.
nisolone, which is widely used for the treatment of glo- The increase in biglycan, occurring concomitantly with
merulonephritis. a decrease in total proteoglycan synthesis, is of particular
Biochemical studies using both conventional column interest. Although the functions of this proteoglycan
chromatography as well as enzyme digestion studies sug- have not yet been fully characterized, it is known that
gested that dexamethasone reduced synthesis of proteo- biglycan, by virtue of its two negatively-charged GAG
glycans of the CS/DSPG class. Comparison of the molec- side-chains, can bind to, and potentially inactivate trans-
ular size of CS/DSPG produced by mesangial cells with forming growth factor (TGF)- [35]. TGF- is a growth
and without dexamethasone treatment did not reveal a promoting cytokine that may play a central role in the
major difference in their size or charge, suggesting that pathogenesis of glomerular sclerosis by acting as a com-
the reduced synthesis of GAG was not caused by a reduc- mon intermediary through which initial injuries of differ-
tion in the length of the GAG side-chains, but by a ent forms (immunologic, metabolic, and mechanical) can
reduction in the number of proteoglycan molecules. lead to the increased collagen deposition and glomerular
Although the renal glomeruli contain multiple cell sclerosis characteristic of scarred kidneys. Of interest,
types (endothelial cells, mesangial cells, and epithelial TGF- itself causes up-regulation of biglycan, and this
cells), it has been shown both biochemically and histolog- is thought to act as an important negative feedback mech-
ically that the major site of CS/DSPG production is the anism to inhibit over-action of this growth factor [36].
mesangial cell [25–27]. Thus, the changes brought about In view of these reports, the glucocorticoid-induced in-
by glucocorticoids in the mesangial cell can be assumed crease in biglycan expression could be of therapeutic
to have a major effect on the glomerular extracellular benefit in inhibiting TGF- and thus attenuating the final
matrix as a whole. common pathway leading to the progression of renal
To further investigate the mechanisms of the changes, disease.
levels of mRNA for the major proteoglycans expressed In this study, we further characterized the molecular
mechanisms of the glucocorticoid-induced changes inby mesangial cells were examined. In the case of the CS/
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biglycan expression. The 5-flanking regions of the bigly- sition of the glomerular basement membrane, our results
can gene in humans and mice have been characterized do not support the view that glucocorticoids act thera-
and shown to have 90% homology [20]. Both promoter peutically by causing major changes in the production
regions are GC rich, contain multiple putative transcrip- of HSPG by the mesangial cell.
tion start sites, and multiple regulatory elements. These In summary, the results of this study demonstrate that
include activator protein-1 (AP-1) and AP-2 sites, in- glucocorticoids can affect glomerular proteoglycan syn-
terleukin-6 responsive elements, nuclear factor-B sites, thesis in vitro and in vivo, and cause distinct changes
and E-boxes. Of interest, two sequences characteristic in proteoglycan core protein expression by mechanisms
of glucocorticoid responsive elements (GREs) have been involving changes in gene transcription. Since proteogly-
located in the 5-flanking region. Consistent with the cans play an important role in the progression of renal
sequence data, transfection of the promoter constructs disease, these results are of interest for understanding
followed by dexamethasone treatment caused an in- some of the mechanisms of actions of glucocorticoids in
crease in promoter activity that was not seen in the renal tissues, which would help in designing newer and
shorter constructs lacking the GREs. These results sup- better strategies for more effective treatment of glomer-
port the view that glucocorticoids up-regulate biglycan ulonephritis.
gene expression in mesangial cells by transcriptional con-
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